Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IPSS Risk Category Intermediate-1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT04324060
What this trial is testing

Trial of rhTPO Versus Placebo for Low/Intermediate-1 Risk MDS With Thrombocytopenia

Who this might be right for
Low/Intermediate Risk-1 MDS
Peking Union Medical College Hospital 75
Not applicableStudy completedNCT04036448
What this trial is testing

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

Who this might be right for
Myelodysplastic SyndromesLymphoma, Mantle-CellLymphoma, Follicular
Celgene 28
Testing effectiveness (Phase 2)Study completedNCT00910858
What this trial is testing

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Who this might be right for
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Celgene Corporation 40
Testing effectiveness (Phase 2)Study completedNCT02335268
What this trial is testing

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia

Who this might be right for
Myelodysplastic Syndromes
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 77
Large-scale testing (Phase 3)Study completedNCT00179621
What this trial is testing

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Who this might be right for
Myelodysplastic Syndromes
Celgene Corporation 205
Large-scale testing (Phase 3)Active Not RecruitingNCT06468033
What this trial is testing

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Who this might be right for
Primary MyelofibrosisMyeloproliferative Neoplasm
PharmaEssentia 160
Testing effectiveness (Phase 2)Study completedNCT01497145
What this trial is testing

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

Who this might be right for
MDS
Kyowa Kirin Co., Ltd. 45
Testing effectiveness (Phase 2)Ended earlyNCT02240706
What this trial is testing

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Boehringer Ingelheim 27
Testing effectiveness (Phase 2)Study completedNCT01178814
What this trial is testing

Revlimid in Transfusion Dependent Patients

Who this might be right for
Myelodysplastic Syndrome
Columbia University 57
Testing effectiveness (Phase 2)Ended earlyNCT00699842
What this trial is testing

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Who this might be right for
Myelodysplastic SyndromeMDSLow to Intermediate-1 MDS+1 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 8
Testing effectiveness (Phase 2)Study completedNCT01736683
What this trial is testing

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
AnemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more
Merck Sharp & Dohme LLC 74
Large-scale testing (Phase 3)Active Not RecruitingNCT00843882
What this trial is testing

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Who this might be right for
AnemiaChronic Myelomonocytic LeukemiaDe Novo Myelodysplastic Syndrome+1 more
National Cancer Institute (NCI) 247
Not applicableStudy completedNCT02378701
What this trial is testing

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 102
Testing effectiveness (Phase 2)WithdrawnNCT00960726
What this trial is testing

NOV-002 in Myelodysplastic Syndrome (MDS)

Who this might be right for
LeukemiaMyelodysplastic Syndrome
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Study completedNCT01243476
What this trial is testing

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Fundación General de la Universidad de Salamanca 61
Testing effectiveness (Phase 2)Study completedNCT02281084
What this trial is testing

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Celgene 65
Testing effectiveness (Phase 2)Study completedNCT02363491
What this trial is testing

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 96
Early research (Phase 1)Study completedNCT01496495
What this trial is testing

ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Array Biopharma, now a wholly owned subsidiary of Pfizer 71
Testing effectiveness (Phase 2)Not Yet RecruitingNCT02944955
What this trial is testing

BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic Syndrome (MDS)
BioLite, Inc. 52
Testing effectiveness (Phase 2)Study completedNCT00619099
What this trial is testing

Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome
Eisai Inc. 67
Next Page